Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $44.00 at JPMorgan Chase & Co.

Travere Therapeutics (NASDAQ:TVTX) had its price objective upped by JPMorgan Chase & Co. from $42.00 to $44.00 in a report issued on Wednesday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

A number of other equities analysts also recently commented on TVTX. Evercore ISI lifted their target price on Travere Therapeutics from $33.00 to $45.00 and gave the company an “outperform” rating in a research note on Wednesday, February 12th. Barclays lifted their target price on Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. Citigroup boosted their price objective on Travere Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a research report on Monday. Canaccord Genuity Group boosted their price objective on Travere Therapeutics from $22.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, February 12th. Finally, HC Wainwright boosted their price objective on Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research report on Wednesday, January 15th. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $30.62.

Travere Therapeutics Stock Performance

Shares of TVTX stock opened at $21.03 on Wednesday. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. The business has a 50 day moving average of $19.90 and a two-hundred day moving average of $16.89. Travere Therapeutics has a 52 week low of $5.12 and a 52 week high of $25.29. The company has a market cap of $1.64 billion, a P/E ratio of -5.13 and a beta of 0.72.

Travere Therapeutics (NASDAQ:TVTX) last issued its earnings results on Thursday, February 20th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.15). Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%. The company had revenue of $74.79 million during the quarter, compared to analyst estimates of $72.38 million. As a group, analysts anticipate that Travere Therapeutics will post -1.4 EPS for the current year.

Insider Buying and Selling

In related news, insider Peter Heerma sold 1,584 shares of the business’s stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $18.94, for a total transaction of $30,000.96. Following the sale, the insider now owns 106,374 shares of the company’s stock, valued at $2,014,723.56. The trade was a 1.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Sandra Calvin sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, December 26th. The stock was sold at an average price of $17.22, for a total value of $258,300.00. Following the sale, the chief accounting officer now directly owns 54,927 shares in the company, valued at approximately $945,842.94. The trade was a 21.45 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 206,335 shares of company stock valued at $4,453,012 over the last quarter. Corporate insiders own 4.06% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TVTX. Creative Planning increased its holdings in shares of Travere Therapeutics by 4.3% in the third quarter. Creative Planning now owns 23,938 shares of the company’s stock valued at $335,000 after buying an additional 995 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Travere Therapeutics by 64.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 14,712 shares of the company’s stock valued at $206,000 after buying an additional 5,767 shares in the last quarter. Rice Hall James & Associates LLC increased its holdings in shares of Travere Therapeutics by 24.4% in the third quarter. Rice Hall James & Associates LLC now owns 94,736 shares of the company’s stock valued at $1,325,000 after buying an additional 18,562 shares in the last quarter. Emerald Mutual Fund Advisers Trust increased its holdings in shares of Travere Therapeutics by 26.0% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 1,185,709 shares of the company’s stock valued at $16,588,000 after buying an additional 244,444 shares in the last quarter. Finally, Emerald Advisers LLC increased its holdings in shares of Travere Therapeutics by 19.8% in the third quarter. Emerald Advisers LLC now owns 1,960,659 shares of the company’s stock valued at $27,430,000 after buying an additional 323,513 shares in the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.